AllermistTM / Avamys® (fluticasone Furoate) Significantly Improved Symptoms Of Seasonal And Perennial Allergic Rhinitis In Clinical Studies

... GlaxoSmithKline (GSK) announced it has submitted applications for both U.S. and European marketing approval for a new medicine to treat the symptoms of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). The medicine (fluticasone furoate) is an enhanced affinity intranasal corticosteroid with the proposed name of AllermistTM in the US and Avamys® in Europe. [click link for full article] ...